FDA Brief

Warning letters Drugs

FDA warning letter to

Molluscumaway LLC

High riskIssued Aug 18, 2023Posted Aug 22, 2023Center for Drug Evaluation and Research | CDER

FDA warned Molluscumaway LLC that its molluscum patches, ointment, and body wash are unapproved new drugs.

What happened

FDA reviewed the company's website and Facebook and Instagram pages in July 2023. FDA found the site offered MolluscumAway Hydrating Patches, Little Skins Smoothing Skin Ointment, and Little Skins Gentle Body Wash with claims that they treat molluscum contagiosum. FDA says these are unapproved new drugs, meaning drugs sold without FDA approval, and that no approved application is in effect.

What FDA found

  1. The products are drugs because the website and social media claims say they diagnose, cure, mitigate, treat, or prevent molluscum contagiosum.

    section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. The products are new drugs because they are not generally recognized as safe and effective for those claimed uses.

    section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. The products are marketed without an FDA-approved application, so introducing them into interstate commerce violates the unapproved new drug provisions.

    sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA asks the company to respond in writing within fifteen working days with the specific steps taken to correct the violations and prevent recurrence. If the company cannot complete corrections in that time, FDA asks it to explain the delay and state when it will finish.

Who should pay attention

  • parents and caregivers of children with skin lesions
  • sellers of children's skin-care products
  • brands making molluscum or skin-lesion treatment claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. MolluscumRx, Inc.

    FDA told MolluscumRx, Inc. of Orlando, Florida that its molluscum lotion and soap are unapproved new drugs sold with unsupported cure claims.

    High risk
  2. Nature’s Innovation, Inc.

    FDA warned Nature’s Innovation over unapproved drugs marketed for molluscum and shingles, including a kit for children.

    High risk
  3. Thrasio, LLC D/B/A ZymaDerm

    FDA warned Thrasio/ZymaDerm that its ZymaDerm for Molluscum is an unapproved new drug marketed without FDA approval.

    High risk
  4. Walmart, Inc

    FDA warned Walmart over selling Naturasil Molluscum Treatment Kit, an unapproved new drug for molluscum.

    High risk